Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

NCT06064890 is registered in ClinicalTrials.gov with AviadoBio Ltd as lead sponsor.

NCT NCT06064890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06064890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Lead sponsor
AviadoBio Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 30, 2023
Completion date
March 21, 2030
Enrollment
18 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, frontotemporal, frontotemporal dementia, ftd, ftd-grn